WallStSmart

ICU Medical Inc (ICUI)vsWest Pharmaceutical Services Inc (WST)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

West Pharmaceutical Services Inc generates 54% more annual revenue ($3.33B vs $2.16B). WST leads profitability with a 17.0% profit margin vs 1.4%. ICUI appears more attractively valued with a PEG of 0.08. WST earns a higher WallStSmart Score of 61/100 (C+).

ICUI

Hold

50

out of 100

Grade: D+

Growth: 2.7Profit: 4.5Value: 7.3Quality: 6.5
Piotroski: 4/9Altman Z: 1.74

WST

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 4.73
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ICUIUndervalued (+53.7%)

Margin of Safety

+53.7%

Fair Value

$319.32

Current Price

$156.48

$162.84 discount

UndervaluedFair: $319.32Overvalued
WSTSignificantly Overvalued (-46.2%)

Margin of Safety

-46.2%

Fair Value

$168.33

Current Price

$346.23

$177.90 premium

UndervaluedFair: $168.33Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ICUI2 strengths · Avg: 9.0/10
PEG RatioValuation
0.0810/10

Growing faster than its price suggests

Price/BookValuation
1.8x8/10

Reasonable price relative to book value

WST3 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.7310/10

Safe zone — low bankruptcy risk

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Operating MarginProfitability
22.5%8/10

Strong operational efficiency at 22.5%

Areas to Watch

ICUI4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.5%4/10

0.5% revenue growth

Altman Z-ScoreHealth
1.744/10

Distress zone — elevated risk

Return on EquityProfitability
2.2%3/10

ROE of 2.2% — below average capital efficiency

Profit MarginProfitability
1.4%3/10

1.4% margin — thin

WST3 concerns · Avg: 2.7/10
Price/BookValuation
8.2x4/10

Trading at 8.2x book value

PEG RatioValuation
2.672/10

Expensive relative to growth rate

P/E RatioValuation
43.5x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : ICUI

The strongest argument for ICUI centers on PEG Ratio, Price/Book. PEG of 0.08 suggests the stock is reasonably priced for its growth.

Bull Case : WST

The strongest argument for WST centers on Altman Z-Score, Debt/Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.

Bear Case : ICUI

The primary concerns for ICUI are Revenue Growth, Altman Z-Score, Return on Equity. A P/E of 135.3x leaves little room for execution misses. Thin 1.4% margins leave little buffer for downturns.

Bear Case : WST

The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 43.5x leaves little room for execution misses.

Key Dynamics to Monitor

ICUI profiles as a value stock while WST is a mature play — different risk/reward profiles.

WST carries more volatility with a beta of 1.14 — expect wider price swings.

WST is growing revenue faster at 13.8% — sustainability is the question.

WST generates stronger free cash flow (81M), providing more financial flexibility.

Bottom Line

WST scores higher overall (61/100 vs 50/100), backed by strong 17.0% margins and 13.8% revenue growth. ICUI offers better value entry with a 53.7% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

ICU Medical Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ICU Medical, Inc. develops, manufactures and sells medical devices used in infusion therapy and critical care applications worldwide. The company is headquartered in San Clemente, California.

West Pharmaceutical Services Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.

Want to dig deeper into these stocks?